logo

中东和非洲糖尿病药物市场 - 增长、趋势、COVID-19 影响和预测（2022 - 2027 年）

中东和非洲糖尿病药物市场按产品类型（口服抗糖尿病药物、胰岛素、非胰岛素注射药物和组合药物）和地理区域划分。

Home Industry Reports Healthcare 中东和非洲糖尿病药物市场 - 增长、趋势、COVID-19 影响和预测（2022 - 2027 年）

市场快照

Middle East & Africa Diabetes Drugs Market Overview
Study Period: 2016-2027
Base Year: 2021
CAGR: 0 %
Middle East & Africa Diabetes Drugs Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

  • 中东和非洲糖尿病药物市场（以下简称市场研究）在 2018 年价值 27.9399 亿美元，预计在 2019-2024 年的预测期内复合年增长率为 6.48%，主要是由于老年人口不断增长。
  • 在中东地区的大多数国家，估计消费者在糖尿病上的花费约为 170 亿美元。
  • 该地区糖尿病人口不断增长的主要原因是不健康的生活方式和城市化。
  • 该地区的大多数国家最近都经历了巨大的经济和工业发展，导致社会行为发生了转变。

报告范围

中东和非洲糖尿病药物市场按产品类型（口服抗糖尿病药物、胰岛素、非胰岛素注射药物和组合药物）和地理区域进行细分。

By Product Type
Oral Anti-diabetic Drugs
Biguanide (Value and Volume 2012-2024)
Metformin
Alpha - Glucosidase Inhibitors (Value and Volume 2012-2024)
Alpha - Glucosidase Inhibitors
Sodium - glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas (Value and Volume 2012-2024)
Sulfonylureas
Meglitinide (Value and Volume 2012-2024)
Meglitinide
Insulin
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humilin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Non-Insulin Injectable Drugs
GLP1 Receptor Agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Combination Drugs
Insulin Combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination
Janumet (Sitagliptin and Metformin HCl)
Geography
Middle East & Africa (Value and Volume, 2012-2024)
Saudi Arabia
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies
Iran
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies
Egypt
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies
Oman
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies
South Africa
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies
Rest of Middle & Africa
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

Report scope can be customized per your requirements. Click here.

主要市场趋势

中东和非洲地区约有 1600 万人患有糖尿病

  • 在中东和非洲 (MEA)，有 1551 万人患有糖尿病，预计这一人群在预测期内将以 4.46% 的复合年增长率增长。
  • 在 MEA 地区，2018 年肥胖率很高，有 4200 万人，占总人口的 21%。肥胖可能在未来导致 2 型糖尿病。
  • 埃及和沙特阿拉伯的糖尿病患者人数最多，分别占所研究市场的 53.3% 和 28.2% 的市场份额。
  • 对于大多数人来说，久坐不动的生活方式和无穷无尽的快餐选择已经取代了传统的工作、旅行和美食方式，增加了患 2 型糖尿病等疾病的机会。
  • 这些国家人口的增加和人均收入的增加可能会导致医疗保健支出的增加，这可能会推动预测期内（2019-2024 年）研究的市场。
Middle East & Africa Diabetes Drugs Market Key Trends

沙特阿拉伯拥有最高的市场份额

  • 沙特阿拉伯在 MEA 糖尿病药物市场中的市场份额最大，2018 年接近 25.35%，预计阿曼在预测期内（2019-2024 年）的增长率最高，为 10.45%。
  • 沙特阿拉伯糖尿病药物销量的增长是由于该国糖尿病患病率的增加。
  • 中东国家的糖尿病患病率很高，如沙特阿拉伯 - 24%、科威特 - 23%、巴林 - 22%、卡塔尔 - 20% 和阿联酋 - 19%。
  • 2018 年，胰岛素在所研究市场中的市场份额接近 33.37%。2018 年中东和北非地区研究的胰岛素市场价值为 9.3227 亿美元，预计在预测期间（2019-2024 年）的复合年增长率为 4.12%，预计沙特阿拉伯将占据 32.33%市场份额。
Middle East & Africa Diabetes Drugs Market Growth by Region

竞争格局

制造商不断推动创新，以在所研究的市场中竞争和挣扎。

  • 被认为是仿制药的 Glynase 和 Diatab 在中东地区销量很高，但被认为低于它们所依据的治疗标准。因此，在沙特食品药品监督管理局（SFDA）的通知下，国家卫生监管局（NHRA）宣布了撤回这些药物的决定。 
  • 一项关于 SGLT2 类（Jardiance，Farxiga）的新研究表明该药物有助于治疗肾脏和心血管疾病。
Takeda, Pfizer, Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, Merck And Co., AstraZeneca, Bristol Myers Squibb, Novartis,

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Oral Anti-diabetic Drugs

        1. 5.1.1.1 Biguanide (Value and Volume 2012-2024)

          1. 5.1.1.1.1 Metformin

        2. 5.1.1.2 Alpha - Glucosidase Inhibitors (Value and Volume 2012-2024)

          1. 5.1.1.2.1 Alpha - Glucosidase Inhibitors

        3. 5.1.1.3 Sodium - glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)

          1. 5.1.1.3.1 Invokana (Canagliflozin)

          2. 5.1.1.3.2 Jardiance (Empagliflozin)

          3. 5.1.1.3.3 Farxiga/Forxiga (Dapagliflozin)

          4. 5.1.1.3.4 Suglat (Ipragliflozin)

        4. 5.1.1.4 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)

          1. 5.1.1.4.1 Januvia (Sitagliptin)

          2. 5.1.1.4.2 Onglyza (Saxagliptin)

          3. 5.1.1.4.3 Tradjenta (Linagliptin)

          4. 5.1.1.4.4 Vipidia/Nesina (Alogliptin)

          5. 5.1.1.4.5 Galvus (Vildagliptin)

        5. 5.1.1.5 Sulfonylureas (Value and Volume 2012-2024)

          1. 5.1.1.5.1 Sulfonylureas

        6. 5.1.1.6 Meglitinide (Value and Volume 2012-2024)

          1. 5.1.1.6.1 Meglitinide

      2. 5.1.2 Insulin

        1. 5.1.2.1 Basal or Long Acting Insulins

          1. 5.1.2.1.1 Lantus (Insulin Glargine)

          2. 5.1.2.1.2 Levemir (Insulin Detemir)

          3. 5.1.2.1.3 Toujeo (Insulin Glargine)

          4. 5.1.2.1.4 Tresiba (Insulin Degludec)

          5. 5.1.2.1.5 Basaglar (Insulin Glargine)

        2. 5.1.2.2 Bolus or Fast Acting Insulins

          1. 5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)

          2. 5.1.2.2.2 Humalog (Insulin Lispro)

          3. 5.1.2.2.3 Apidra (Insulin Glulisine)

        3. 5.1.2.3 Traditional Human Insulins

          1. 5.1.2.3.1 Novolin/Actrapid/Insulatard

          2. 5.1.2.3.2 Humilin

          3. 5.1.2.3.3 Insuman

        4. 5.1.2.4 Biosimilar Insulins

          1. 5.1.2.4.1 Insulin Glargine Biosimilars

          2. 5.1.2.4.2 Human Insulin Biosimilars

      3. 5.1.3 Non-Insulin Injectable Drugs

        1. 5.1.3.1 GLP1 Receptor Agonists

          1. 5.1.3.1.1 Victoza (Liraglutide)

          2. 5.1.3.1.2 Byetta (Exenatide)

          3. 5.1.3.1.3 Bydureon (Exenatide)

          4. 5.1.3.1.4 Trulicity (Dulaglutide)

          5. 5.1.3.1.5 Lyxumia (Lixisenatide)

      4. 5.1.4 Combination Drugs

        1. 5.1.4.1 Insulin Combinations

          1. 5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)

          2. 5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

          3. 5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

        2. 5.1.4.2 Oral Combination

          1. 5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)

    2. 5.2 Geography

      1. 5.2.1 Middle East & Africa (Value and Volume, 2012-2024)

        1. 5.2.1.1 Saudi Arabia

          1. 5.2.1.1.1 Oral Anti-diabetic Drugs

          2. 5.2.1.1.2 Insulin

          3. 5.2.1.1.3 Non-Insulin Injectable Drugs

          4. 5.2.1.1.4 Combination Drugs

          5. 5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

        2. 5.2.1.2 Iran

          1. 5.2.1.2.1 Oral Anti-diabetic Drugs

          2. 5.2.1.2.2 Insulin

          3. 5.2.1.2.3 Non-Insulin Injectable Drugs

          4. 5.2.1.2.4 Combination Drugs

          5. 5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

        3. 5.2.1.3 Egypt

          1. 5.2.1.3.1 Oral Anti-diabetic Drugs

          2. 5.2.1.3.2 Insulin

          3. 5.2.1.3.3 Non-Insulin Injectable Drugs

          4. 5.2.1.3.4 Combination Drugs

          5. 5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

        4. 5.2.1.4 Oman

          1. 5.2.1.4.1 Oral Anti-diabetic Drugs

          2. 5.2.1.4.2 Insulin

          3. 5.2.1.4.3 Non-Insulin Injectable Drugs

          4. 5.2.1.4.4 Combination Drugs

          5. 5.2.1.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

        5. 5.2.1.5 South Africa

          1. 5.2.1.5.1 Oral Anti-diabetic Drugs

          2. 5.2.1.5.2 Insulin

          3. 5.2.1.5.3 Non-Insulin Injectable Drugs

          4. 5.2.1.5.4 Combination Drugs

          5. 5.2.1.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

        6. 5.2.1.6 Rest of Middle & Africa

          1. 5.2.1.6.1 Oral Anti-diabetic Drugs

          2. 5.2.1.6.2 Insulin

          3. 5.2.1.6.3 Non-Insulin Injectable Drugs

          4. 5.2.1.6.4 Combination Drugs

          5. 5.2.1.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetic Population (2012-2024)

    2. 6.2 Type-2 Diabetic Population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Takeda

      2. 7.1.2 Pfizer

      3. 7.1.3 Eli Lilly

      4. 7.1.4 Janssen Pharmaceuticals

      5. 7.1.5 Astellas

      6. 7.1.6 Boehringer Ingelheim

      7. 7.1.7 Merck And Co.

      8. 7.1.8 AstraZeneca

      9. 7.1.9 Bristol Myers Squibb

      10. 7.1.10 Novartis

      11. 7.1.11 Sanofi

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The MEA Diabetes Drugs Market market is studied from 2016 - 2027.

The MEA Diabetes Drugs Market is growing at a CAGR of 0% over the next 5 years.

Boehringer Ingelheim, Astrazeneca, Eli Lilly, Sanofi, Novo Nordisk are the major companies operating in MEA Diabetes Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!